FDA gains power to penalize influencers for false drug claims on social media

What it does

This bill creates new FDA enforcement authority to penalize social media influencers and health care providers who make false or misleading claims about prescription drugs without required safety information, and requires disclosure of payments between drug manufacturers and influencers or telehealth providers. It also funds FDA surveillance of drug promotion on social media and requires HHS to issue guidance on enforcement within 180 days.

Why we flagged it

The bill's core mechanism is to expand FDA authority to penalize false or misleading drug claims on social media and require disclosure of payments to influencers and providers. It is fundamentally a consumer-protection and public-health measure, not a market-driven or industry-favoring provision.

What the text implies

• The definition of 'false or misleading communications' requires knowledge or recklessness, creating a scienter requirement that may limit enforcement against negligent or careless influencers who lack intent to deceive.
• Telehealth providers are explicitly brought within the scope of regulation as 'manufacturers' if they connect patients to prescribers, potentially expanding liability for platforms that merely facilitate prescribing without directly promoting drugs.
• The 180-day guidance requirement and 1-year regulatory update timeline may create enforcement uncertainty during the interim period, potentially delaying accountability for ongoing deceptive promotion.
• AI-powered surveillance of social media drug promotion (section (c)(1)(A)(i)) may capture and analyze private communications or statements not intended as advertising, raising privacy concerns despite the bill's public-health intent.
• The carve-out for 'statements that describe the person's own experience, opinion, or value judgment' may allow influencers to evade liability by framing false claims as personal testimony rather than promotional statements.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients are protected from false or misleading drug claims on social media by holding influencers and providers accountable for omitting required safety information. The bill increases FDA's capacity to monitor and enforce against deceptive promotion, reducing the risk that patients will be misled into unsafe or ineffective drug use.

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), FTC (Federal Trade Commission), Social media platforms, Prescription drug manufacturers, Telehealth providers, Social media influencers, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Office of Prescription Drug Promotion

Where it stands

1 cosponsor: 1 Republicans.

• Feb 20, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Feb 20, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S1129-1130)”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 4 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $16,740,000 in lobbying spend. A filing names 58 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Richard Durbin, the sponsor, reported $-29,800 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing
• Alliance for Safe Online Pharmacies (asop Global) — $80,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.